OnkoRisk Hereditary Urology Panel
- GTR Test IDHelpEach Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. When a laboratory updates a registered test, a new version number is assigned.: GTR000613040.1
- Last updated: 2023-10-20
- Test version history
- 613040.1, last updated: 2023-10-20
Clinical testHelpIn the U.S., clinical tests must be performed under CLIA certification. When a lab uses the same methods for a test in both clinical and research settings, the test appears as two separate GTR records. for Malignant tumor of prostate
Offered by BioReference Health
Overview
Test name
HelpThe name the laboratory assigns the test. Used as the default title of the page specific to the test.OnkoRisk Hereditary Urology Panel
This is a clinical test intended for HelpPurposes or indications for the test. Lab-provided.: Diagnosis, Pre-symptomatic, Risk Assessment
Click Indication tab for more information.
Not provided
Specimen source
Methodology
HelpThe assay's major method category (biochemical, cytogenetic or molecular genetics); method category (i.e. enzyme assay, chromosome breakage studies, targeted mutation analysis); methodology (i.e. the name of the method used) and instruments used when performing this test.- Molecular Genetics
- CSequence analysis of the entire coding region
- Next-Generation (NGS)/Massively parallel sequencing (MPS)
- Illumina NovaSeq
Not provided
Clinical validity
HelpHow consistently and accurately the test detects or predicts the intermediate or final outcomes of interest. Lab-provided.Clinical validity is dependent on individual patient clinical picture and family history of disease.
Citations
Not provided
Test services
HelpLaboratory's order or catalog code for the test (used in the order requisition form).- Genetic counseling, Order code: TQ06, TQ07
- NCI PDQ, Prostate cancer geneticsGenetics of Prostate Cancer (PDQ®): Health Professional Version
- NCI PDQ, Cancer Genetics CounselingCancer Genetics Risk Assessment and Counseling (PDQ®): Health Professional Version
- NCCN, 2024NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Prostate Cancer, 2024
- NICE, 2023UK NICE Guideline NG12, Suspected cancer: recognition and referral, 2023
- NICE, 2021UK NICE Guideline NG131, Prostate cancer: diagnosis and management, 2021
- NCCN, 2011NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.
- OMIM
- View AR variations in ClinVar
- View ZFHX3 variations in ClinVar
- View BRCA2 variations in ClinVar
- View CDH1 variations in ClinVar
- View KLF6 variations in ClinVar
- View MXI1 variations in ClinVar
- View PTEN variations in ClinVar
- View MAD1L1 variations in ClinVar
- View CHEK2 variations in ClinVar
- RefSeqGene
- Coriell Institute for Medical Research
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.